Cancer Advances Inc.

Quick facts

Phase 2 pipeline

• G17DT-Irinotecan · Oncology
  G17DT-Irinotecan is a topoisomerase I inhibitor, which works by blocking the enzyme topoisomerase I and preventing DNA replication in cancer cells.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cancer Advances Inc. portfolio CI brief
• Cancer Advances Inc. pipeline updates RSS